Molecule
Nifurtimox is a prescription medicine indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis) caused by Trypanosoma cruzi. MedsAcross supplies Nifurtimox for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
LAMPIT is indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis) caused by Trypanosoma cruzi. LAMPIT is a nitrofuran antiprotozoal, indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis), caused by Trypanosoma cruzi.
Source: US FDA prescribing information
Nifurtimox is an antiprotozoal drug. Mechanism of Action The mechanism of action of nifurtimox is not fully understood. Studies suggest that nifurtimox is metabolized/activated, by Type I (oxygen insensitive) and Type II (oxygen sensitive) nitoreductases (NTR) leading to production of toxic intermediate metabolites and/or reactive oxygen species that induce DNA damage and cell death of both intracellular and extracellular forms of T. cruzi.
Source: US FDA prescribing information
• LAMPIT tablets must be taken with food. Dosage of LAMPIT in Pediatric Patients (birth a to less than 18 years of age). Body Weight Group Total Daily Dose of nifurtimox (mg/kg) 41 kg or greater 8 to 10 Less than 41 kg 10 to 20 a Term newborn with body weight greater than or equal to 2.5 kg • Administer LAMPIT tablets orally, three times daily with food for 60 days. • Obtain a pregnancy test in females of reproductive potential prior to initiating treatment with LAMPIT. • See Full Prescribing Information for additional important administration instructions.
Source: US FDA prescribing information
LAMPIT tablets are contraindicated in: • Patients with known hypersensitivity to nifurtimox or any of the excipients in LAMPIT. • Patients who consume alcohol during treatment • Known hypersensitivity to nifurtimox or to any of the excipients in LAMPIT. • Alcohol consumption during treatment.
Source: US FDA prescribing information
• Potential for Genotoxicity and Carcinogenicity. • Embryo-Fetal Toxicity: May cause fetal harm. Pregnancy testing is recommended for females of reproductive potential. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. Advise males to use condoms with female partners of reproductive potential. • Worsening Neurological and Psychiatric Conditions: Patients with a history of brain injury, seizures, psychiatric disease, serious behavioral alterations may experience worsening of their conditions when receiving LAMPIT. Administer LAMPIT under close medical supervision in these patients or if neurological disturbances or psychiatric drug reactions occur.
Source: US FDA prescribing information
The following serious or otherwise important adverse reactions are discussed elsewhere in the labeling: • Potential for Genotoxicity, Carcinogenicity, and Mutagenicity • Worsening of Neurological and Psychiatric Conditions • Hypersensitivity • Decreased Appetite and Weight Loss • Porphyria The most frequently reported adverse reactions (≥5%) are vomiting, abdominal pain, headache, decreased appetite, nausea, pyrexia, and rash.
Source: US FDA prescribing information
Concomitant use of LAMPIT with alcohol may increase the incidence and severity of undesirable effects similar to other nitrofurans and nitroheterocyclic compounds. LAMPIT is contraindicated in patients who consume alcohol during treatment.
Source: US FDA prescribing information
Store at controlled room temperature 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Store LAMPIT tablets in the original bottle with child-resistant closures and do not remove the desiccant. Keep bottle with child-resistant closures tightly closed and protect from moisture.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Nifurtimox, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Lampit 120 mg tabletOral | Bayer HealthCare Pharmaceuticals | US FDA | Available on request |
| Lampit 30 mg tabletOral | Bayer HealthCare Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 6 August 2020 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Nifurtimox in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 2 presentations of Nifurtimox and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Nifurtimox, including Lampit.
Yes. The US FDA first approved Nifurtimox on 6 August 2020, according to Drugs@FDA.
No listed presentation of Nifurtimox is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Nifurtimox is classified under ATC code P01CC01 (Nifurtimox).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.